Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Piramal Pharma Limited ( (IN:PPLPHARMA) ) just unveiled an update.
Piramal Pharma Limited has overhauled its senior management structure, designating four executives as Senior Management Personnel: Chief Quality Officer Rashida Najmi, President – Mergers and Acquisitions Jatin Lal, General Counsel Sandeep Rathod and Chief Human Resource Officer Puneet Rajput. The move signals a greater emphasis on quality, deal-making, legal governance and talent management as core pillars of the company’s operations. In parallel, the board has accepted the resignation of Company Secretary and Compliance Officer Tanya Sanish, effective 20 February 2026, and appointed Pratibha Mishra as Interim Company Secretary and Compliance Officer from 21 February 2026, ensuring continuity in corporate governance and regulatory compliance amid the leadership transition.
More about Piramal Pharma Limited
Piramal Pharma Limited is an India-based pharmaceutical company focused on developing, manufacturing and marketing a range of pharma products and services. Listed on the BSE and NSE, it operates under India’s SEBI listing framework and maintains a broad stakeholder base that includes public shareholders and institutional investors.
Average Trading Volume: 222,676
Technical Sentiment Signal: Sell
Current Market Cap: 201.2B INR
Find detailed analytics on PPLPHARMA stock on TipRanks’ Stock Analysis page.